Table 2.

Demographic and clinical characteristics in responder v/s nonresponder and naïve v/s NAs-experienced CHB patients.

		Analogues antiviral therapy		Significance p<0.05)	Analogues antiviral therapy		Significance p<0.05)
		responder (n=28)	nonresponder (n=26)		Naïve (n=27)	NAs experienced (n=27)
Gender (male/female)		10/18	19/7	0.0066	11/16	18/9	0.10
Age (years)		43.4±1.98	54.4±3.51	0.011	47.67±3.3	49.70±2.59	0.62
ALT (IU/l)		136±41	76±11	0.75	120±40	95±20	0.74
Baseline viral load (kIU/ml)		13702±8385	57857±15205	0.0035	33989±12765	35935±12814	0.98
HBe Ag (reactive/nonreactive)		8/20	15/11	0.033	9/18	14/14	0.25
HBe Ab (reactive/nonreactive)		21/7	12/14	0.032	19/8	14/13	0.25
Baseline HBV drug-resistant variants* (Yes/No)		19/9	17/9	0.86	13/14	23/4	0.019
Immunocompromised (Yes/No)		10/17	8/17	0.71	8/19	10/15	0.52
NAs therapy** (naïve/experienced)		13/15	14/12	0.60	NA$	NA##	NA##
Antiviral therapy	Lamivudine	16	14	0.029	23	7	0.0001
	Entecavir	6	10		4	12
	Tenofovir	6	1		0	7
	lamivudine + adefovir	0	1		0	1
Liver biopsy#	inflammation grade	2	2	0.50	1.75	2	0.70
	fibrosis stage	1.5	1.5	0.99	1.5	1.5	0.42

Data are presented as a mean value ± standard error (SE);

^#data presented as a median value;

^*the presence of HBV drug-resistant minor variant before NAs therapy;

^**nucleoside/nucleotide analogues therapy;

^##not applicable.